Comparision of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) in Patients with Post Kidney Transplant (Ktx)

Trial Profile

Comparision of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) in Patients with Post Kidney Transplant (Ktx)

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolic acid (Primary) ; Sirolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2017 New trial record
    • 03 May 2017 Results presented at the 2017 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top